Anavex Life Sciences Corp.: stock overview

AVXLNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$0.59

November 20, 2026Market cap $53M

What Ploutos Investor adds for Anavex Life Sciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from FY2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 80% since Aug 28, 2026, when the 10-Q these figures come from was filed ($2.99 then, $0.59 on Nov 20, 2026). The figures date from before that move.10-Q
  • The latest annual figures the company filed are for 2025, more than a year ago. Newer ones may be late.

In short

It pays no dividend.

From its SEC filings (latest fiscal year to September 30, 2025) and the price of November 20, 2026.

Its SEC filings
Market cap
$53M
89.35M shares
P/E
–
Revenue, 12 months
–
Net margin
–

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

FY2023–FY2025 fiscal years
  • FY2025Sep 30, 202510-K
    Revenue–
  • FY2024Sep 30, 202410-K
    Revenue–
  • FY2023Sep 30, 202310-K
    Revenue–

Fiscal years in figures

AVXL's revenue, profit, cash flow and dividend with each year-end price, from FY2009 to FY2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $538M
$53M
Enterprise value 
–
P/E 
–
EV / EBIT 
–
EV / Revenue 
–
P/B 3-year median: 4.0
0.5
FCF yield 
–
Earnings yield 3-year median: -9.2%
–

Profitability

Net margin 
–
ROIC 
-42.8%
ROIC, 5-year average 
-31.8%
ROE 
-11.9%

Growth

Sorry, we do not have enough data

for the “Growth” group

Balance sheet

Cash 
$118M
Total debt 
–
Net cash 
–
Net debt / EBITDA 
–
Interest cover 
–
Current ratio 
–

Balance sheet of June 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+5.3%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
ANAVEX LIFE SCIENCES CORP.
Exchange
NASDAQ
Industry (SIC)
2836 · Biological Products, (No Diagnostic Substances)
Fiscal year ends
September 30
Latest annual report
September 30, 2025
Reporting currency
USD
Shares
89.35M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Anavex Life Sciences's filings show?

These are Anavex Life Sciences's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about AVXL

Didn't find what you were looking for?

Ask us
What is AVXL's market cap?

Anavex Life Sciences Corp.'s market cap is $53M, at a price of $0.59 on November 20, 2026 and 89.35M shares.

Does AVXL pay a dividend?

No. Anavex Life Sciences paid no regular dividend over the last 12 months.

Where do the figures come from?

From Anavex Life Sciences Corp.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.